Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29027368 | 0.68 | ALDH1A1 (0.60) | ALDH1A1 | |
| SCHEMBL197155 | 0.64 | CA12 (0.35) | — | |
| SCHEMBL311916 | 0.62 | ACHE (0.33) | ALDH1A1 | |
| SCHEMBL4061519 | 0.61 | L3MBTL1 (0.33) | ALDH1A1 | |
| SCHEMBL4060260 | 0.61 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL20611991 | 0.60 | — | — | |
| SCHEMBL25403571 | 0.59 | — | — | |
| SCHEMBL8932301 | 0.59 | — | — | |
| SCHEMBL4067084 | 0.58 | — | — | |
| SCHEMBL9979581 | 0.57 | CYP3A4 (0.38) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108137547-B | Heterocyclic compounds useful as TNF alpha modulators | 百时美施贵宝公司 | 2021-11-12 | — | — | CN | claimed |
| US-10865191-B2 | Heterocyclic compounds useful as modulators of TNF alpha | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-12-15 | — | — | US | claimed |
| US-20180222883-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF TNF ALPHA | BRISTOL MYERS SQUIBB CO (US) | 2018-08-09 | — | — | US | claimed |
| EP-3331871-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF TNF ALPHA | Bristol-Myers Squibb Company (US) | 2018-06-13 | — | — | EP | claimed |
| WO-2017023905-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF TNF ALPHA | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-02-09 | — | — | WO | claimed |
| CN-108137547-B | Heterocyclic compounds useful as TNF alpha modulators | 百时美施贵宝公司 | 2021-11-12 | — | — | CN | disclosed |
| US-10865191-B2 | Heterocyclic compounds useful as modulators of TNF alpha | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-12-15 | — | — | US | disclosed |
| US-20180222883-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF TNF ALPHA | BRISTOL MYERS SQUIBB CO (US) | 2018-08-09 | — | — | US | disclosed |
| EP-3331871-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF TNF ALPHA | Bristol-Myers Squibb Company (US) | 2018-06-13 | — | — | EP | disclosed |
| US-9962377-B2 | Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors | TAKEDA GMBH (DE) | 2018-05-08 | — | — | US | disclosed |
| WO-2017023905-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF TNF ALPHA | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-02-09 | — | — | WO | disclosed |
| US-20160279120-A1 | NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | TAKEDA GMBH (DE) | 2016-09-29 | — | — | US | disclosed |
| US-8324391-B2 | Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors | NYCOMED GMBH (DE) | 2012-12-04 | — | — | US | disclosed |
| US-8318944-B2 | Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors | NYCOMED GMBH (DE) | 2012-11-27 | — | — | US | disclosed |
| US-20110257169-A1 | NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | NYCOMED GMBH (DE) | 2011-10-20 | — | — | US | disclosed |
| US-20110257221-A1 | NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | NYCOMED GMBH (DE) | 2011-10-20 | — | — | US | disclosed |
| US-8003798-B2 | Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors | NYCOMED GMBH (DE) | 2011-08-23 | — | — | US | disclosed |
| US-20080167301-A1 | Respiratory system disorders | ALTANA PHARMA AG (DE) | 2008-07-10 | — | — | US | disclosed |
| EP-1723135-A1 | NOVEL HYDROXY-6-HEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | Altana Pharma AG (DE) | 2006-11-22 | — | — | EP | disclosed |
| WO-2005085225-A1 | NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | ALTANA PHARMA AG (DE) | 2005-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10865191-B2 | Heterocyclic compounds useful as modulators of TNF alpha | TNF, TNFRSF9, TNFRSF1A | ALDH1A1 2515/4885 |
| US-20180222883-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF TNF ALPHA | TNF, TNFRSF9, TNFRSF1A | ALDH1A1 2515/4885 |
| US-20110257221-A1 | NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE4C | ALDH1A1 273/4885 |
| US-20110257169-A1 | NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE4C | ALDH1A1 273/4885 |
| US-20160279120-A1 | NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | PDE4A, PDE12, PDE4B | ALDH1A1 148/4885 |
| US-20080167301-A1 | Respiratory system disorders | PDE4A, PDE4B, PDE12 | ALDH1A1 300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.